Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

YTYun Kyoung TigerRutgers, The State University of New JerseyRARoshan AsraniIcahn School of Medicine at Mount SinaiANAdrienne NedvedMayo Clinic in Arizona

Discussion

Loading...

Member takes

Implication

Multicenter retrospective study shows Glofit-GemOx yields 78% overall response rate in relapsed/refractory aggressive B-cell lymphoma, indicating potential as effective therapy.

Key Points

  • To evaluate the real-world efficacy of Glofit plus GemOx in patients with relapsed/refractory aggressive B-cell lymphoma.
  • Conducted a multicenter retrospective study across 8 U.S. academic centers.
  • Identified 31 patients with relapsed/refractory aggressive B-cell lymphoma treated with Glofit-GemOx.
  • Abstracted data on baseline characteristics, treatment history, and outcomes from medical records.
  • Overall response rate (ORR) was 78% in evaluable patients.
  • Complete response (CR) rate was 41% among all evaluable cases.
  • Majority of patients had advanced stage disease, with 90% presenting with stage III/IV.

Cite This Study

Tiger et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5aahttps://doi.org/10.1182/blood-2025-1956
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups2025 · 3 citations
  2. 2Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO2025 · 3 citations
  3. 3Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  4. 4Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  5. 5Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO2026